ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RENE Reneuron Group Plc

3.05
0.00 (0.00%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 530k -5.41M -0.0946 -0.32 1.74M
Reneuron Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 3.05p. Over the last year, Reneuron shares have traded in a share price range of 2.95p to 10.25p.

Reneuron currently has 57,173,760 shares in issue. The market capitalisation of Reneuron is £1.74 million. Reneuron has a price to earnings ratio (PE ratio) of -0.32.

Reneuron Share Discussion Threads

Showing 7901 to 7921 of 8900 messages
Chat Pages: Latest  320  319  318  317  316  315  314  313  312  311  310  309  Older
DateSubjectAuthorDiscuss
07/5/2020
12:54
I once went out with a girl. She was nice
volsung
07/5/2020
12:51
Or people who were girls? Or people who weren't?
ayl30
07/5/2020
12:47
Are there girls here!?
small crow
07/5/2020
12:34
Thanks for the links/info guys...and girls of course!
rayrac
07/5/2020
12:23
Nice news today. A bit of information here on the work:



"We used CTX neuron stem cells, developed by ReNeuron in the U.K., " Professor Song said. "The candidate is already in phase 2 clinical trials with stroke patients in the U.K. and the U.S., and the safety and efficacy of the cells have already been proven."

lauders
07/5/2020
08:55
Great news for sufferers and their families. This should progress to the clinic and licensing in double-quick time. This is what the original paper says:

-----
Significance statement
This study investigated the effects of clinical‐grade neural stem cells manufactured from a conditionally immortalized cell line, CTX0E03, which is currently in a phase IIb clinical trial in the United States in patients with moderate to severe disability after ischemic stroke, on an animal model of Huntington's disease (HD). The results demonstrated that intracerebral transplantation of CTX0E03 cells can lead to significant improvements in the behavioral and pathological deficits of a rodent model of HD by both cell replacement and host cell regeneration mechanisms. Therefore, this study provides a strong basis for clinical development of these cells to treat HD patients in the future.
-----

There are no meaningful treatment options for HD at the moment, as far as I'm aware, so the HD Association will be desperately anxious to see this moved through trials rapidly. To get an idea of the impact the disease has try googling 'Huntingtons right to die' or similar - very depressing indeed. This potential treatment offers hope to those who previously had none. Well done RENE!

supernumerary
07/5/2020
08:45
The new data published today show that implantation of CTX cells into a model of Huntington's disease can reduce inflammation, glial scar formation and induce host neurogenesis (the generation of new brain cells) leading to a recovery in behavioural deficits.

ReNeuron said the results are particularly encouraging as they also demonstrate that CTX, a well-characterised neural stem cell line that has been evaluated in multiple pre-clinical and clinical studies, can differentiate into medium spiny neurons, engraft into the host tissue and form functional connections with the surrounding tissue.

"The data being published today represent a significant advance in the potential use of human allogeneic stem cell lines as therapeutic candidates for the treatment of Huntington's disease,” Dr Randolph Corteling, the head of research at ReNeuron said in a statement.

“Importantly, the immortalisation technology found within ReNeuron's CTX cell line allows for the scaled production of 'off the shelf' human neural stem cells, with the potential to treat a variety of different neurological disorders," he added.

uk2day
07/5/2020
08:23
Red army! Ditto chart looks great imo!, bear trap Has been completed!, now looks to be headed back up along with fundamentals to back it!

Huge market if successful!!!㈇7;

uk2day
07/5/2020
08:20
The data being published today represent a significant advance in the potential use of human allogeneic stem cell lines as therapeutic candidates for the treatment of Huntington's disease. Importantly, the immortalisation technology found within ReNeuron's CTX cell line allows for the scaled production of 'off the shelf' human neural stem cells, with the potential to treat a variety of different neurological disorders."
uk2day
07/5/2020
08:17
Added to my position this morning - nice inverted head and shoulders.
red army
07/5/2020
07:49
Yes, what else can one say?
rayrac
07/5/2020
07:06
Good RNS today...
bonzo
27/4/2020
11:41
Nice mover today and good to be been able to pick up cheaply, being off folk's radars (only for the moment).

f

fillipe
17/4/2020
19:49
So,the stuff works well, and needs to be tweeked a bit to complete all that is expected of it. Come on RENE!
alimo
13/4/2020
17:41
Cell therapy restores mobility and sensations in rodent models of stroke

Scientists at Lund University in Sweden showed long ago they could reprogram human cells into nerve cells and implant them into the brains of rats after a stroke. But would the cells form the vital connections needed to restore mobility and sensations like touch?

Now, they have early evidence that the answer to that question is yes. The Lund team turned skin cells into nerve cells, transplanted them into the brains of the rodent stroke models and observed them for six months. The new cells repaired the damage caused by strokes in the animals, the researchers reported in the journal PNAS.

The Lund University team transplanted the reprogrammed skin cells into the rats’ cerebral cortices, the region of the brain that’s most commonly damaged by stroke. Then they used electron microscopy and other technologies to track the cells. That allowed them to see that the cells were making the connections needed to repair damaged nerve circuits.

“We have been able to see that the fibers from the transplanted cells have grown to the other side of the brain, the side where we did not transplant any cells, and created connections,” said co-author Zaal Kokaia, professor of neurology at Lund, in a statement.

Cell therapy has been proposed for treating stroke damage in the past, but efforts to make it a reality have hit some roadblocks. A stem cell therapy being developed by British biotech ReNeuron failed to hit its primary trial endpoint of improving arm and leg movements. ReNeuron has since turned in better results from a trial of its cell therapy for improving vision in patients with retinitis pigmentosa.

Meanwhile, academic researchers are testing a variety of other therapies aimed at repairing stroke damage. Last year, for example, Stanford researchers showed that blocking a particular microRNA prompted star-shaped brain cells called astrocytes to become neurons, which helped restore memory in rats.

The Lund team is now planning additional animal trials to study how their transplanted cells affect memory and other intellectual functions, they said. They will also watch the rats closely to make sure they aren’t experiencing side effects, and they’ll study the impact of the transplants on regions of the brain.



Nuance on the 'failure':

supernumerary
09/4/2020
21:31
The downward trend was completed with the third wave, and surely we're now in the third wave of five for this upward trend. Get on board cos the third wave isn't finished yet and two more to come.
alimo
09/4/2020
09:41
RENE - really going for it these past few days.

Another nice uptick today....lowest ask on show now 163p.

f

fillipe
08/4/2020
13:12
Lol! That was years ago, bit risky, even for me. Got it on watch tho, more than I can say for Opti!

I’m letting the share price speak for itself, both here and Opti.👉ӿ99;😂

rayrac
08/4/2020
13:09
could be worse bpc looooooooool raytard a disaster
manc10
08/4/2020
08:41
rene 3rd may 19 price 315p now 127p its done well raytard loooooool
manc10
07/4/2020
23:20
Better bet than Opti, that’s for sure! Manc is a waster from the Opti threads. Very nasty piece of work.
rayrac
Chat Pages: Latest  320  319  318  317  316  315  314  313  312  311  310  309  Older

Your Recent History

Delayed Upgrade Clock